解放军医学院学报2015，Vol.36Issue(6)：634-636,643,4.DOI:10.3969/j.issn.2095-5227.2015.06.031
唑来膦酸在乳腺癌中抗肿瘤作用的研究进展
Advances in antitumor effects of zoledronic acid in breast cancer
摘要
Abstract
Zoledronic acid (ZOL) is the third generation of bisphosphonates (BPs) that has been used as the standard treatment of osseous metastasis in breast cancer and it plays a role in treating breast cancer by inhibiting bone destruction mediated by osteoclast. Recently, many researchfindings indicate that ZOL can inhibit tumor cells directly or indirectly, furthermore, we alsofind that the antitumor effect of ZOL is enhanced when combined with chemotherapy. Many clinical trials data indicate that ZOL also plays a role in both preventing relapse and reducing the probability of skeletal and visceral metastases after surgery. The present review assesses the available preclinical and clinical evidence of the antitumor effect of ZOL in treating breast cancer.关键词
乳腺癌/唑来膦酸/骨转移/抗肿瘤药物Key words
breast cancer/zoledronic acid/bone metastasis/antitumor drug分类
医药卫生引用本文复制引用
邱镜丹,李荣,王建东..唑来膦酸在乳腺癌中抗肿瘤作用的研究进展[J].解放军医学院学报,2015,36(6):634-636,643,4.基金项目
北京市自然科学基金项目(7142151) Supported by the Natural Science Foundation of Beijing (7142151) （7142151）
